Syk-Specific Inhibitors

Description

  • Novel, oral small molecules that selectively inhibit Syk, an important mediator of immune response in a number of different types of immune cells
  • Collaborating with Ora, Inc. to develop for treatment of inflammatory diseases

Clinical Development

  • Portola and Ora, Inc. are evaluating the Syk-selective inhibitor PRT2761 as a potential treatment for allergic conjunctivitis